Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Comprehensive Mutational Analysis of Primary and Relapse Acute Promyelocytic Leukemia Publisher Pubmed



Madan V1 ; Shyamsunder P1 ; Han L1, 2 ; Mayakonda A1 ; Nagata Y3 ; Sundaresan J1 ; Kanojia D1 ; Yoshida K3 ; Ganesan S4 ; Hattori N1 ; Fulton N5 ; Tan KT1 ; Alpermann T6 ; Kuo MC7 Show All Authors
Authors
  1. Madan V1
  2. Shyamsunder P1
  3. Han L1, 2
  4. Mayakonda A1
  5. Nagata Y3
  6. Sundaresan J1
  7. Kanojia D1
  8. Yoshida K3
  9. Ganesan S4
  10. Hattori N1
  11. Fulton N5
  12. Tan KT1
  13. Alpermann T6
  14. Kuo MC7
  15. Rostami S8
  16. Matthews J9
  17. Sanada M3
  18. Liu LZ1
  19. Shiraishi Y10
  20. Miyano S10
  21. Chendamarai E4
  22. Hou HA11
  23. Malnassy G5
  24. Ma T12
  25. Garg M1
  26. Ding LW1
  27. Sun QY1
  28. Chien W1
  29. Ikezoe T13
  30. Lill M14
  31. Biondi A15
  32. Larson RA16
  33. Powell BL17
  34. Lubbert M12
  35. Chng WJ1, 2, 18
  36. Tien HF11
  37. Heuser M19
  38. Ganser A19
  39. Korenmichowitz M20, 21
  40. Kornblau SM9
  41. Kantarjian HM9
  42. Nowak D22
  43. Hofmann WK22
  44. Yang H1
  45. Stock W5
  46. Ghavamzadeh A8
  47. Alimoghaddam K8
  48. Haferlach T6
  49. Ogawa S3
  50. Shih LY7
  51. Mathews V4
  52. Koeffler HP1, 14, 18
Show Affiliations
Authors Affiliations
  1. 1. Cancer Science Institute of Singapore, National University of Singapore, 14 Medical Drive, 13-01, Singapore, 117599, Singapore
  2. 2. Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
  3. 3. Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
  4. 4. Department of Haematology, Christian Medical College, Vellore, India
  5. 5. Section of Hematology/Oncology, University of Chicago, Chicago, IL, United States
  6. 6. Munich Leukemia Laboratory (MLL), Munich, Germany
  7. 7. Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung University, Taoyuan, Taiwan
  8. 8. Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran
  9. 9. Section of Molecular Hematology and Therapy, University of Texas, MD Anderson Cancer Center, Houston, TX, United States
  10. 10. Laboratory of DNA Information Analysis, Human Genome Center, University of Tokyo, Tokyo, Japan
  11. 11. Department of Internal Medicine, National Taiwan University, Medical College and Hospital, Taipei, Taiwan
  12. 12. Division of Hematology, Oncology and Stem Cell Transplantation, Department of Internal Medicine, University of Freiburg Medical Center, Freiburg, Germany
  13. 13. Department of Hematology and Respiratory Medicine, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan
  14. 14. Cedars-Sinai Medical Center, Division of Hematology/Oncology, UCLA School of Medicine, Los Angeles, CA, United States
  15. 15. Paediatric Haematology-Oncology Department, Milano-Bicocca University, San Gerardo Hospital, Monza, Italy
  16. 16. Department of Medicine, University of Chicago, Comprehensive Cancer Center, Chicago, IL, United States
  17. 17. Department of Internal Medicine, Comprehensive Cancer Center, Wake Forest University, Winston-Salem, NC, United States
  18. 18. Department of Hematology-Oncology, National University Cancer Institute of Singapore (NCIS), National University Health System (NUHS), Singapore, Singapore
  19. 19. Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
  20. 20. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
  21. 21. Division of Hematology and Bone Marrow Transplantation, Sheba Medical Center, Tel Hashomer, Israel
  22. 22. Department of Hematology and Oncology, University Hospital Mannheim, University of Heidelberg, Mannheim, Germany

Source: Leukemia Published:2016


Abstract

Acute promyelocytic leukemia (APL) is a subtype of myeloid leukemia characterized by differentiation block at the promyelocyte stage. Besides the presence of chromosomal rearrangement t(15;17), leading to the formation of PML-RARA (promyelocytic leukemia-retinoic acid receptor alpha) fusion, other genetic alterations have also been implicated in APL. Here, we performed comprehensive mutational analysis of primary and relapse APL to identify somatic alterations, which cooperate with PML-RARA in the pathogenesis of APL. We explored the mutational landscape using whole-exome (n=12) and subsequent targeted sequencing of 398 genes in 153 primary and 69 relapse APL. Both primary and relapse APL harbored an average of eight non-silent somatic mutations per exome. We observed recurrent alterations of FLT3, WT1, NRAS and KRAS in the newly diagnosed APL, whereas mutations in other genes commonly mutated in myeloid leukemia were rarely detected. The molecular signature of APL relapse was characterized by emergence of frequent mutations in PML and RARA genes. Our sequencing data also demonstrates incidence of loss-of-function mutations in previously unidentified genes, ARID1B and ARID1A, both of which encode for key components of the SWI/SNF complex. We show that knockdown of ARID1B in APL cell line, NB4, results in large-scale activation of gene expression and reduced in vitro differentiation potential. © 2016 Macmillan Publishers Limited.
Related Docs
3. Tumor Antigens, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)
4. Tumor Antigens, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)
Experts (# of related papers)